Equity Investment or Strategic Collaboration with Chinese Biotech that Have Innovative Technology Platforms

Focus on developing class one natural fully human mAb biologicals

Hitmab R&D platform: Developing natural fully human mAb with high safety, broad spectrum to foreign pathogens and strong affinity with pathogen targets

Main Products

Fully Human Anti-SA Hlα Antibody
A natural fully human anti-staphylococcus aureus (SA) antibody drug with Hlα neutralizing activity
Fully Human Anti-HCMV Antibody
A natural fully human antibody drug with human cytomegalovirus (HCMV) neutralizing activity
Fully Human Anti-COVID-19 Antibody
A natural fully human anti-COVID-19 antibody effectively against major current strains with low immunogenicity
Fully Human Anti-rabies Virus Antibody
An accessible natural fully human anti-rabies virus antibody with low immunogenicity and high affinity

Focusing on the research, development and industrialization of bispecific antibody drugs


Main Products

VEGF+ANG2 Tetravalent Bispecific Antibody
Achieving stronger effectiveness and lower dosing frequency compared with existing anti-VEGF drugs